Biomerieux, Inc.

Dade Behring Inc.

Cambridge University Hospitals Nhs Foundation Trust

Hema Doobay

Liliana M Tejidor

Timothy J Fischer

Trevor Baglin

Jianfang Wang

Kevin Bruce Johnson

Roger Luddington

Liliana Tejidor

A reagent and kit are disclosed for determining if a patient is hypercoagulable, hypocoagulable or normal. The test involves providing a test sample from the patient and initiating coagulation in the sample in the presence of an activator, which is added to the sample in an amount which will result in intrinsic tenase-dependent fibrin. Then the formation of the intrinsic tenase-dependent fibrin polymerization is monitored over time so as to derive a time-dependent profile, with the results of the fibrin polymerization monitoring determining whether the patient is hypercoagulable, normal or hypocoagulable. The coagulation activator is added in an amount that triggers a thrombin explosion that is dependent on the propagation phase and amplification pathways. In this way, a single assay can assess the hemostatic potential of a sample.

Reagent and kit for determining global coagulability and hemostatic potential

The present invention relates generally to the field of prothrombin time reagents for determining dysfunction in the coagulation system and more specifically to reagents made from native thromboplastin or purified or recombinant tissue factor and phospholipids from a natural or synthetic source. The present invention relates to methods to make a diagnostic reagent that includes a membrane-bound protein incorporated into a liposome and having additional empty liposomes (liposomes without membrane-bound protein incorporated therein) added to the solution.

Use of liposomes of defined composition and size for the preparation of prothrombin time reagents

Growing community of inventors

Raleigh, NC, United States of America

Hema Doobay